{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:14:04Z","timestamp":1792800844264,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Investigator Grant from the National Health and Medical Research Council of Australia","award":["Investigator grant 2008129"],"award-info":[{"award-number":["Investigator grant 2008129"]}],"id":[{"id":"https:\/\/ror.org\/011kf5r70","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council of Singapore","doi-asserted-by":"crossref","award":["Clinician Scientist Award"],"award-info":[{"award-number":["Clinician Scientist Award"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Massachussetts General Hospital","award":["Adolph Hutter Professorship"],"award-info":[{"award-number":["Adolph Hutter Professorship"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic myocardial disorder (DbMD, evidenced by abnormal echocardiography or cardiac biomarkers) is a form of stage B heart failure (SBHF) at high risk for progression to overt HF. SBHF is defined by abnormal LV morphology and function and\/or abnormal cardiac biomarker concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the evolution of four DbMD groups based on biomarkers alone, systolic and diastolic dysfunction alone, or their combination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure (ARISE-HF) trial was a Phase 3 randomised trial of an aldose reductase inhibitor in patients with well-controlled type 2 diabetes mellitus (T2DM). The 1858 potential participants (age 67\u2009\u00b1\u20097\u00a0years; 50% women) were screened for SBHF based on abnormal echocardiography or biomarkers (N-terminal pro-B-type natriuretic peptide\u2009\u2265\u200940\u00a0ng\/L or high sensitivity cardiac troponin T\u2009\u2265\u200910\u00a0ng\/L [women] and\u2009\u2265\u200916\u00a0ng\/L [men]). Exercise capacity (peak VO\n                      <jats:sub>2<\/jats:sub>\n                      ) was reduced in 669 with DbMD (age 68\u2009\u00b1\u20097, 50% women), and peak VO\n                      <jats:sub>2<\/jats:sub>\n                      was reassessed at 15\u00a0months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 1463 (79%) participants with DbMD were allocated to four clusters; 907 (49%) showed\n                      <jats:italic>isolated elevation of cardiac biomarkers<\/jats:italic>\n                      , 301 (16%) with\n                      <jats:italic>systolic dysfunction\/hypertrophy<\/jats:italic>\n                      , 162 (9%) with\n                      <jats:italic>diastolic dysfunction<\/jats:italic>\n                      and 93 (5%) comprised an\n                      <jats:italic>overlap cluster<\/jats:italic>\n                      (combined diastolic, systolic or LV geometric abnormalities). Reduced VO\n                      <jats:sub>2<\/jats:sub>\n                      (&lt;\u200975% predicted) was present in 669 (46%); 72% of those with both systolic and diastolic dysfunction, 56% of those with systolic dysfunction and LVH, 53% of those with diastolic dysfunction and 38% with biomarkers alone (p\u2009&lt;\u20090.0001). In 669 patients followed over 15\u00a0months, there was a similar small decrement in VO\n                      <jats:sub>2<\/jats:sub>\n                      in all groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among individuals with T2DM and SBHF, reduced functional capacity is most prevalent in those with multiple physiological disturbances. However, there was no difference between phenogroups in the evolution of exercise intolerance.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial Registration<\/jats:italic>\n                      : ARISE-HF, NCT04083339.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-024-02554-y","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T14:37:49Z","timestamp":1736779069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15\u00a0months follow-up in the ARISE-HF trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Thomas H.","family":"Marwick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ezekowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrien E.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. H. Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Perfetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"2554_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/ejhf.2144","volume":"23","author":"RJ Woolley","year":"2021","unstructured":"Woolley RJ, Ceelen D, Ouwerkerk W, et al. Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23:983\u201391.","journal-title":"Eur J Heart Fail"},{"key":"2554_CR2","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.2337\/dci22-0014","volume":"45","author":"R Pop-Busui","year":"2022","unstructured":"Pop-Busui R, Januzzi JL, Bruemmer D, et al. Heart failure: an underappreciated complication of diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care. 2022;45:1670\u201390.","journal-title":"Diabetes Care"},{"key":"2554_CR3","doi-asserted-by":"crossref","unstructured":"Bozkurt B, Coats AJ, Tsutsui H et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart failure. J Card Fail 2021.","DOI":"10.1002\/ejhf.2115"},{"key":"2554_CR4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3389\/fendo.2018.00729","volume":"9","author":"J Zheng","year":"2018","unstructured":"Zheng J, Cheng J, Zheng S, et al. Physical exercise and its protective effects on diabetic cardiomyopathy: What is the evidence? Front Endocrinol (Lausanne). 2018;9:729.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2554_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","volume":"20","author":"PM Seferovic","year":"2018","unstructured":"Seferovic PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:853\u201372.","journal-title":"Eur J Heart Fail"},{"key":"2554_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman MS, Bhatt DL, Hameed I, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024;12:447\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2554_CR7","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","volume":"403","author":"J Butler","year":"2024","unstructured":"Butler J, Shah SJ, Petrie MC, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403:1635\u201348.","journal-title":"Lancet"},{"key":"2554_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","volume":"30","author":"S Rubler","year":"1972","unstructured":"Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30:595\u2013602.","journal-title":"Am J Cardiol"},{"key":"2554_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41569-020-0339-2","volume":"17","author":"Y Tan","year":"2020","unstructured":"Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17:585\u2013607.","journal-title":"Nat Rev Cardiol"},{"key":"2554_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","volume":"71","author":"TH Marwick","year":"2018","unstructured":"Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. 2018;71:339\u201351.","journal-title":"J Am Coll Cardiol"},{"key":"2554_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13098-023-00998-y","volume":"15","author":"J Deng","year":"2023","unstructured":"Deng J, Yan F, Tian J, Qiao A, Yan D. Potential clinical biomarkers and perspectives in diabetic cardiomyopathy. Diabetol Metab Syndr. 2023;15:35.","journal-title":"Diabetol Metab Syndr"},{"key":"2554_CR12","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jacc.2017.07.792","volume":"70","author":"L Ernande","year":"2017","unstructured":"Ernande L, Audureau E, Jellis CL, et al. Clinical implications of echocardiographic phenotypes of patients with diabetes Mellitus. J Am Coll Cardiol. 2017;70:1704\u201316.","journal-title":"J Am Coll Cardiol"},{"key":"2554_CR13","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.jcmg.2018.03.015","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Yang H, Huynh Q, Nolan M, Negishi K, Marwick TH. Diagnosis of nonischemic stage B Heart failure in type 2 diabetes Mellitus: optimal parameters for prediction of heart failure. JACC Cardiovasc Imaging. 2018;11:1390\u2013400.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2554_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ahj.2022.11.003","volume":"256","author":"JL Januzzi Jr","year":"2023","unstructured":"Januzzi JL Jr., Butler J, Del Prato S, et al. Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart failure trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy. Am Heart J. 2023;256:25\u201336.","journal-title":"Am Heart J"},{"key":"2554_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1161\/CIRCOUTCOMES.115.001958","volume":"8","author":"JA Spertus","year":"2015","unstructured":"Spertus JA, Jones PG. Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire. Circ Cardiovasc Qual Outcomes. 2015;8:469\u201376.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2554_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0895-4356(93)90053-4","volume":"46","author":"RA Washburn","year":"1993","unstructured":"Washburn RA, Smith KW, Jette AM, Janney CA. The physical activity scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46:153\u201362.","journal-title":"J Clin Epidemiol"},{"key":"2554_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","volume":"32","author":"C Mitchell","year":"2019","unstructured":"Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32:1\u201364.","journal-title":"J Am Soc Echocardiogr"},{"key":"2554_CR18","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.jcmg.2019.03.032","volume":"12","author":"FA Flachskampf","year":"2019","unstructured":"Flachskampf FA, Blankstein R, Grayburn PA, et al. Global longitudinal shortening: a positive step towards reducing confusion surrounding global longitudinal strain. JACC Cardiovasc Imaging. 2019;12:1566\u20137.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2554_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ehf2.12257","volume":"5","author":"Y Wang","year":"2018","unstructured":"Wang Y, Yang H, Nolan M, Pathan F, Negishi K, Marwick TH. Variations in subclinical left ventricular dysfunction, functional capacity, and clinical outcomes in different heart failure aetiologies. ESC Heart Fail. 2018;5:343\u201354.","journal-title":"ESC Heart Fail"},{"key":"2554_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jchf.2022.12.005","volume":"11","author":"X Jia","year":"2023","unstructured":"Jia X, Al Rifai M, Ndumele CE, et al. Reclassification of Pre-heart failure stages using Cardiac biomarkers: the ARIC Study. JACC Heart Fail. 2023;11:440\u201350.","journal-title":"JACC Heart Fail"},{"key":"2554_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/1479164115579006","volume":"12","author":"CS Lam","year":"2015","unstructured":"Lam CS. Diabetic cardiomyopathy: an expression of stage B heart failure with preserved ejection fraction. Diab Vasc Dis Res. 2015;12:234\u20138.","journal-title":"Diab Vasc Dis Res"},{"key":"2554_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1161\/CIRCULATIONAHA.123.067530","volume":"149","author":"KV Patel","year":"2024","unstructured":"Patel KV, Segar MW, Klonoff DC, et al. Optimal screening for Predicting and preventing the risk of heart failure among adults with diabetes without atherosclerotic Cardiovascular Disease: a pooled cohort analysis. Circulation. 2024;149:293\u2013304.","journal-title":"Circulation"},{"key":"2554_CR23","doi-asserted-by":"crossref","unstructured":"Nagori A, Segar MW, Keshvani N et al. Prevalence and predictors of subclinical cardiomyopathy in patients with type 2 diabetes in a Health System. J Diabetes Sci Technol 2023:19322968231212219.","DOI":"10.1177\/19322968231212219"},{"key":"2554_CR24","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.jacc.2021.08.020","volume":"78","author":"MW Segar","year":"2021","unstructured":"Segar MW, Khan MS, Patel KV, et al. Prevalence and prognostic implications of Diabetes with Cardiomyopathy in Community-Dwelling adults. J Am Coll Cardiol. 2021;78:1587\u201398.","journal-title":"J Am Coll Cardiol"},{"key":"2554_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-020-01109-1","volume":"19","author":"L Nesti","year":"2020","unstructured":"Nesti L, Pugliese NR, Sciuto P, Natali A. Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach. Cardiovasc Diabetol. 2020;19:134.","journal-title":"Cardiovasc Diabetol"},{"key":"2554_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.tips.2018.02.010","volume":"39","author":"X Palomer","year":"2018","unstructured":"Palomer X, Pizarro-Delgado J, Vazquez-Carrera M. Emerging actors in Diabetic Cardiomyopathy: heartbreaker biomarkers or therapeutic targets? Trends Pharmacol Sci. 2018;39:452\u201367.","journal-title":"Trends Pharmacol Sci"},{"key":"2554_CR27","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1111\/j.1532-5415.2010.03068.x","volume":"58","author":"ES Nylen","year":"2010","unstructured":"Nylen ES, Kokkinos P, Myers J, Faselis C. Prognostic effect of exercise capacity on mortality in older adults with diabetes mellitus. J Am Geriatr Soc. 2010;58:1850\u20134.","journal-title":"J Am Geriatr Soc"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02554-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02554-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02554-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T14:37:57Z","timestamp":1736779077000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02554-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2554"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02554-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"27 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Marwick has received research support from General Electric Medical Systems, and is on the Steering Committee for the ARISE-HF trial (Applied Therapeutics). Dr Lam has received research support from NovoNordisk and Roche Diagnostics; has Served as consultant or on the Advisory Board\/ Steering Committee\/ Executive Committee for Alleviant Medical, Allysta Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, Cytokinetics, Darma Inc., EchoNous Inc, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape\/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Quidel Corporation, Radcliffe Group Ltd., Recardio Inc, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Ms. Liu has no disclosures.Dr. Del Prato has served as president of EASD\/European Foundation for the Study of Diabetes (EFSD) (2020\u20132022); has received research grants to the institution from AstraZeneca and Boehringer Ingelheim; has served as advisor for Abbott, Amarin Corporation, Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., EvaPharma, Jiangsu Hengrui Pharmaceuticals Co., Menarini International, Merck Sharpe & Dohme, Novartis Pharmaceutical Co., Novo Nordisk, Sanofi and Sun Pharmaceuticals; and has received fees for speaking from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Laboratori Guidotti, Menarini Itarnational, Merck Sharpe & Dohme and Novo Nordisk. Dr. Rosenstock has served on scientific advisory boards and received honorarium or consulting fees from Applied Therapeutics, Biomea Fusion, Boehringer Ingelheim, Eli Lilly, Endogenex, Hanmi, Novo Nordisk, Oramed, Regor, Sanofi, Scholar Rock, Structure Therapeutics, Terns Pharma and Zealand; and has received grants\/research support from Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi, Merck, Oramed, Novartis, Novo Nordisk, Pfizer and Sanofi. Dr. Butler is a consultant to Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Pfizer, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, and Zoll; Dr. Ezekowitz reports research support for trial leadership or grants from American Regent, Applied Therapeutics, AstraZeneca, Bayer, Cytokinetics, Merck & Co, Novo Nordisk, Otsuka; honoraria for consultancy from AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Otsuka; serves as an advisor to US2.aiDr. Ibrahim reports consulting income from Cytokinetics and honoraria from Applied Therapeutics; Dr. Tang is a consultant for Sequana Medical, Cardiol Therapeutics Inc, Genomics plc, Zehna Therapeutics, Boston Scientific, WhiteSwell, Kiniksa Pharmaceuticals, Intellia Therapeutics, CardiaTec Biosciences, Bristol Myers Squibb, Alleviant Medical, and has received honorarium from Springer, Belvoir Media Group, and American Board of Internal Medicine; Dr. Zannad reports personal fees from 89bio, Applied Therapeutics, Bayer, Betagenon, Biopeutics, Boehringer, BMS, CVRx, Cardior, Cambrian, Cereno pharmaceutical, Cellprothera, CEVA, Merck, Northsea, Novartis, NovoNordisk, Otsuka, Owkin, Salubris, Servier, having stock options at G3Pharmaceutical and equities at Cereno pharmaceutical, Cardiorenal, Eshmoun Clinical research and being the founder of CVCT. Dr Perfetti is an employee of Applied Therapeutics, Inc. Dr. Januzzi is a Trustee of the American College of Cardiology, is a Board Member of Imbria Pharmaceuticals, is a director at Jana Care, has received research support from Abbott, Applied Therapeutics, HeartFlow Inc, Innolife and Roche Diagnostics, consulting income from Abbott, AstraZeneca, Bayer, Beckman, Boehringer-Ingelheim, Janssen, Novartis, Merck, and Roche Diagnostics, and participates in clinical endpoint committees\/data safety monitoring boards for Abbott, AbbVie, Bayer, CVRx, Intercept, Pfizer and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}